Findings
stroke, cognitive impairment
STROKE
In this randomized clinical trial of 363 participants treated with ISMN, cilostazol, ISMN-cilostazol, or no study drug in a 2 × 2 factorial design, 99% of patients were retained at 1 year with good study drug adherence and no safety concerns. Isosorbide mononitrate reduced recurrent stroke and cognitive impairment, cilostazol reduced dependence, and ISMN-cilostazol reduced the composite of adverse vascular, dependence, and cognitive outcomes.